Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | DGKA | P23743 | 2/20 | 0.64 |
| ▸ | PAM | P19021 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 4/20 | 0.53 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | PRKCA | P17252 | 1/20 | 0.49 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.49 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.49 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20570495 | 1.00 | TSHR (0.70) | TSHRDGKAPAMMAPTLMNA | |
| SCHEMBL22126648 | 1.00 | TSHR (0.70) | TSHRDGKAPAMMAPTLMNA | |
| SCHEMBL5668563 | 1.00 | TSHR (0.70) | TSHRDGKAPAMMAPTLMNA | |
| SCHEMBL22126642 | 1.00 | TSHR (0.70) | TSHRDGKAPAMMAPTLMNA | |
| SCHEMBL22126638 | 1.00 | TSHR (0.70) | TSHRDGKAPAMMAPTLMNA | |
| SCHEMBL10411 | 1.00 | TSHR (0.70) | TSHRDGKAPAMMAPTLMNA | |
| SCHEMBL5666555 | 0.98 | TSHR (0.67) | TSHRDGKAPAMMAPTLMNA | |
| SCHEMBL250417 | 0.92 | TSHR (0.58) | TSHRDGKAPAMMAPTLMNA | |
| SCHEMBL18036999 | 0.91 | DGKA (0.60) | TSHRDGKAMAPTLMNADUSP3 | |
| SCHEMBL11507812 | 0.87 | TSHR (0.50) | TSHRDGKAPAMMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11274073-B2 | TRPV1 modulator compounds | ANTALGENICS, S.L. (ES) | 2022-03-15 | — | — | US | disclosed |
| US-20200199063-A1 | TRPV1 Modulator Compounds | ANTALGENICS, S.L. (ES) | 2020-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11274073-B2 | TRPV1 modulator compounds | TRPV1, TRPA1, TRPV3 | TSHR 530/4885DGKA 1936/4885PAM 2264/4885 |
| US-20200199063-A1 | TRPV1 Modulator Compounds | TRPV1, TRPA1, TRPV3 | TSHR 530/4885DGKA 1936/4885PAM 2264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.